GB
Therapeutic Areas
BetaGlue Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| YntraDose | Unresectable Locally Advanced Pancreatic Ductal Adenocarcinoma (uLA-PDAC) | Phase 1 |
Leadership Team at BetaGlue Therapeutics
AP
Alexis Peyroles
Chief Executive Officer (CEO)
SC
Salvatore Calabrese
Chief Financial Officer (CFO)
DG
Dr. Gianluca De Danieli
Head of Clinical Development
PB
Pietro Bubba Bello
Head of Manufacturing & Operations
DP
Dr. Pieter Janssen
Head of Product Development
DC
Dr. Carol Hegarty
Head of Clinical Operations